{"denoms":[{"counts":[{"groupId":"BG000","value":"270"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"405"}],"units":"Participants"}],"groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"BG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"BG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"116"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"289"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45","upperLimit":"90","value":"70"},{"groupId":"BG001","lowerLimit":"47","upperLimit":"92","value":"71"},{"groupId":"BG002","lowerLimit":"45","upperLimit":"92","value":"70"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"270"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"405"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"216"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"319"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"79"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"302"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"80"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"167"}]}],"title":"North America"},{"categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"214"}]}],"title":"Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"11"}]}],"title":"Israel"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"200"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"205"}],"title":"1"}]}],"description":"Measure Description: Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. ECOG 0 = Fully active, able to carry on all pre-disease performance without restriction. ECOG 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (eg, light house work or office work)","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status (at stratification)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"44"}],"title":"BRCA1"},{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"258"}],"title":"BRCA2"},{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"103"}],"title":"ATM"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gene Alteration (at stratification)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.1","upperLimit":"1247","value":"26.9"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"1039","value":"28.8"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"1247","value":"27.8"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Baseline prostate specific antigen (PSA)","unitOfMeasure":"ng/ml"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"269"}]}]}],"description":"The scale for the Gleason score ranges from 2 to 10, with higher scores indicating a worse prognosis","paramType":"COUNT_OF_PARTICIPANTS","title":"Gleason score ≥8 at diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"161"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Measurable Disease per Independent Radiological Review (IRR)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"235"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"349"}]}],"title":"Bone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"178"}]}],"title":"Nodal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"120"}]}],"title":"Visceral"}],"description":"Participants may be counted in more than one category","paramType":"COUNT_OF_PARTICIPANTS","title":"Metastases site(s) by IRR","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"74"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"331"}],"title":"≥1"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Therapies for CRPC","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"230"}]}],"title":"Abiraterone acetate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]}],"title":"Apalutamide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"180"}]}],"title":"Enzalutamide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"91"}]}],"title":"Docetaxel for hormone-sensitive prostate cancer"}],"description":"Participants may be counted in more than one category","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior therapy (2nd generation androgen receptor pathway inhibitor (ARPI) or docetaxel only)","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) Population included all randomized participants (participants with breast cancer gene \\[BRCA\\] mutated metastatic castration-resistant prostate cancer \\[mCRPC\\] and participants with ataxia- telangiectasia mutated serine/threonine kinase \\[ATM\\] mutated mCRPC)."}